“So in genomics, we expect to see better comps as an example.”

In context

“t movement since January and, you know, that could very well come back. And so we've decided now to hold back on resettor, hold back on the second half FX, and just kind of see see what happens especially in a pretty dynamic, you know, policy and operating environment just felt felt like, you know, we'll we'll we'll sit and see how things play out before we commit to that final fifteen twenty seven. Rainer Blair: Yeah. And to the second part, Tycho, I mean, what we're really saying is the first half in the life science segment was down low singles. We expect the full year to be flat, so the second half needs to be up positive low singles. And what we're really seeing there is the impact of three factors. The first is and we're actually not assuming a significantly improved activity level. So in genomics, we expect to see better comps as an example. So in China, we're seeing it's incrementally firmer with some stimulus dollars following through. And then as you suggested, we have a number of new product introductions that are gaining track funnels here in the first half, including Ciox. And Beckman Coulter Life Sciences and some others. And so we expect those to gain traction here in the second half. Maybe to put some numbers around it for you, Tycho. Your sort of best step up from one half to two half to go from down low single to upload single life sciences. Call it $150 million. Roughly. And I think if you if you are kind of trying to bridge that I would say that genomics again, remember the first half, we had those two large customers really fall off. I think that's probably a third of it. I would say that we are assuming China,”